Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection

G. Gerna, M. Zavattoni, E. Percivalle, P. Grossi, M. Torsellini, M. G. Revello

Research output: Contribution to journalArticle

Abstract

In 7 of 18 solid-organ transplant recipients with primary human cytomegalovirus (HCMV) infection, HCMV antigenemia levels were unexpectedly found to rise significantly (P = 0.018) during a mean time of 7.3 ± 3.2 days after initiation of specific antiviral treatment, whereas corresponding levels of viremia dropped significantly (P = 0.043). Thus, shifting to an alternative antiviral drug based solely on increasing antigenemia levels is not justified in this group of patients.

Original languageEnglish
Pages (from-to)1113-1116
Number of pages4
JournalJournal of Clinical Microbiology
Volume36
Issue number4
Publication statusPublished - 1998

    Fingerprint

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this